420 related articles for article (PubMed ID: 33322962)
1. Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism.
Perez-Paramo YX; Lazarus P
Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):333-349. PubMed ID: 33322962
[No Abstract] [Full Text] [Related]
2. Pathways to precision medicine in smoking cessation treatments.
Chen LS; Horton A; Bierut L
Neurosci Lett; 2018 Mar; 669():83-92. PubMed ID: 27208830
[TBL] [Abstract][Full Text] [Related]
3. Implications of gene-drug interactions in smoking cessation for improving the prevention of chronic degenerative diseases.
Quaak M; van Schayck CP; Knaapen AM; van Schooten FJ
Mutat Res; 2009 Jul; 667(1-2):44-57. PubMed ID: 19028511
[TBL] [Abstract][Full Text] [Related]
4. Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.
Allenby CE; Boylan KA; Lerman C; Falcone M
J Neuroimmune Pharmacol; 2016 Sep; 11(3):471-83. PubMed ID: 26872457
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacogenetics in the treatment of tobacco addiction].
Quaak M; van Schooten FJ; van Schayck CP
Tijdschr Psychiatr; 2013; 55(11):891-8. PubMed ID: 24242150
[TBL] [Abstract][Full Text] [Related]
6. Helping smokers quit through pharmacogenetics.
Lerman C
LDI Issue Brief; 2006; 11(6):1-4. PubMed ID: 16827222
[TBL] [Abstract][Full Text] [Related]
7. Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT.
Wells QS; Freiberg MS; Greevy RA; Tyndale RF; Kundu S; Duncan MS; King S; Abney L; Scoville E; Beaulieu DB; Gatskie V; Tindle HA
Nicotine Tob Res; 2018 Nov; 20(12):1489-1496. PubMed ID: 29059367
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics and nicotine addiction treatment.
Munafò MR; Shields AE; Berrettini WH; Patterson F; Lerman C
Pharmacogenomics; 2005 Apr; 6(3):211-23. PubMed ID: 16013953
[TBL] [Abstract][Full Text] [Related]
9. From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.
Salloum NC; Buchalter ELF; Chanani S; Espejo G; Ismail MS; Laine RO; Nageeb M; Srivastava AB; Trapp N; Trillo L; Vance E; Wenzinger M; Hartz SM; David SP; Chen LS
Pharmacogenomics; 2018 Jul; 19(10):861-871. PubMed ID: 29914292
[TBL] [Abstract][Full Text] [Related]
10. Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis.
Thomas KH; Dalili MN; López-López JA; Keeney E; Phillippo D; Munafò MR; Stevenson M; Caldwell DM; Welton NJ
Health Technol Assess; 2021 Oct; 25(59):1-224. PubMed ID: 34668482
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic Optimization of Smoking Cessation Treatment.
Chenoweth MJ; Tyndale RF
Trends Pharmacol Sci; 2017 Jan; 38(1):55-66. PubMed ID: 27712845
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of nicotine addiction: role of dopamine.
Herman AI; DeVito EE; Jensen KP; Sofuoglu M
Pharmacogenomics; 2014 Feb; 15(2):221-34. PubMed ID: 24444411
[TBL] [Abstract][Full Text] [Related]
13. Tobacco addiction and pharmacogenetics of nicotine metabolism.
Swan GE; Lessov-Schlaggar CN
J Neurogenet; 2009; 23(3):262-71. PubMed ID: 19152209
[TBL] [Abstract][Full Text] [Related]
14. Genetics and smoking cessation improving outcomes in smokers at risk.
Lerman CE; Schnoll RA; Munafò MR
Am J Prev Med; 2007 Dec; 33(6 Suppl):S398-405. PubMed ID: 18021915
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
Cahill K; Stevens S; Perera R; Lancaster T
Cochrane Database Syst Rev; 2013 May; 2013(5):CD009329. PubMed ID: 23728690
[TBL] [Abstract][Full Text] [Related]
16. Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.
Smith LC; George O
Neuropharmacology; 2020 Nov; 178():108225. PubMed ID: 32758566
[TBL] [Abstract][Full Text] [Related]
17. Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment.
Bozinoff N; Le Foll B
Expert Rev Respir Med; 2018 Sep; 12(9):793-804. PubMed ID: 30092681
[TBL] [Abstract][Full Text] [Related]
18. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.
King DP; Paciga S; Pickering E; Benowitz NL; Bierut LJ; Conti DV; Kaprio J; Lerman C; Park PW
Neuropsychopharmacology; 2012 Feb; 37(3):641-50. PubMed ID: 22048466
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence.
Hays JT; Ebbert JO
Drugs; 2010 Dec; 70(18):2357-72. PubMed ID: 21142259
[TBL] [Abstract][Full Text] [Related]
20. A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.
Robles GI; Singh-Franco D; Ghin HL
Clin Ther; 2008 May; 30(5):800-12. PubMed ID: 18555928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
